ACIU Stock: The Big Alzheimer’s News That Has AC Immune Skyrocketing Today

AC Immune (NASDAQ:ACIU) stock is rising higher on Tuesday after revealing positive results from an Alzheimer’s disease study.

man's head breaking apart representing ACIU Stock.

Source: pathdoc /

The study, which is being conducted by AC Immune’s partner Genentech, reported positive cognitive results for anti-tau monoclonal antibody, semorinemab. This was being used to treat patients suffering from mild-to-moderate Alzheimer’s disease.

According to a press release from AC Immune, this is the first time that clinical activity has been recorded from such a treatment. This saw the study meeting one of two of its co-primary endpoints. However, it failed to meet the other one.

Professor Andrea Pfeifer, CEO of AC Immune, said the following about the news sending ACIU stock higher today.

“Scientifically, these data are encouraging for the therapeutic strategies targeting Tau. We look forward to additional data from our other clinical-stage Tau programs: Tau vaccine ACI-35, partnered with Janssen; and the small molecule Morphomer® Tau aggregation inhibitor, partnered with Eli Lilly.”

Genentech notes that it will continue the open label portion of the study following these results. It also plans to submit the current data for presentation at the (Clinical Trials on Alzheimer’s Disease conference. That will take place this November.

ACIU stock is getting extra attention today thanks to the Alzheimer’s study news. As of this writing, more than 87 million shares of the stock have changed hands. That’s a massive surge compared to its daily average trading volume of about 467,000 shares.

ACIU stock was up 29.9% as of Tuesday afternoon.

Of course, we’ve got more stock market news for traders to jump into below!

InvestorPlace offers up daily coverage of the stock market and today is no different. Take a look at what has shares of Sequential Brands (NASDAQ:SQBG), Lightning eMotors (NYSE:ZEV), and Corsair Gaming (NASDAQ:CRSR) stock on the move today at the following links!

More Tuesday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC